email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Mini Review(ISSN: 2641-1652)

Advanced Hepatocellular Carcinoma in A Scottish Population – Current Experience and the Future

Volume 1 - Issue 3

Baxter MA1,2*, Peters AL1, Graham J1,3

  • Author Information Open or Close
    • 11Beatson West of Scotland Cancer Centre, Glasgow, UK
    • 2University of Dundee, UK
    • 3University of Glasgow, UK

    *Corresponding author: Dr Mark A Baxter, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, UK Email: markbaxter3@nhs.net

Received: August 07, 2018;   Published: August 10, 2018

DOI: 10.32474/CTGH.2018.01.000112

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in a Scottish population as well as discuss the evidence behind new potential therapies.

Keywords: Sorafenib; Hepatocellular carcinoma; HCC

Abbreviations: HCC: Hepatocellular Carcinoma; PS: Performance Status; OS: Overall Survival; TACE: Transarterial Chemoembolization; VEGF: Vascular Endothelial Growth Factor; PDGFR: Platelet Derived Growth Factor Receptor; FGFR: Fibroblast Growth Factor Receptor; WoS: West of Scotland

Abstract| Introduction| Results and Discussion| Conclusion| References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )